StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.

Recs

0
Player Avatar pchop123 (71.80) Submitted: 2/3/2012 12:27:08 PM : Outperform Start Price: $1.08 STEM Score: -4.07

stem cells may be gaining momentum again

Featured Broker Partners


Advertisement